Volume 14, Number 10—October 2008
Research
Prophylaxis after Exposure to Coxiella burnetii
Claire E. Moodie
, Herbert A. Thompson, Martin I. Meltzer, and David L. Swerdlow
, Herbert A. Thompson, Martin I. Meltzer, and David L. Swerdlow
Table 2
Probability of adverse events associated with postexposure prophylactic antimicrobial agents
| Level of adverse event | Doxycycline* |
Trimethoprim-sulfamethoxazole† |
|||
|---|---|---|---|---|---|
| Best estimate | Upper bound† | Best estimate | Upper bound | ||
| Moderate | 1.01% | 3.03% | 3.90% | 11% | |
| Severe | 0.01% | 0.03% | 0.00123% | 0.00370%‡ | |
| Death | 0.00% | 0.01% | 0.00037% | 0.00111% | |
*Recommended for the general population and high-risk populations based on estimated use of 100 mg orally 2×/d for 5 d.
†Recommended for pregnant women based on 160 mg/800 mg orally 2×/d for the duration of the pregnancy.
‡Arbitrary upper-bound, 3× best estimate (see text for further details).
Page created: July 13, 2010
Page updated: July 13, 2010
Page reviewed: July 13, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.